{"drugs":["Thiola","Tiopronin"],"mono":{"0":{"id":"615025-s-0","title":"Generic Names","mono":"Tiopronin"},"1":{"id":"615025-s-1","title":"Dosing and Indications","sub":{"0":{"id":"615025-s-1-4","title":"Adult Dosing","mono":"<b>Cystinuria:<\/b> initial, 800 mg\/day ORALLY in 3 divided doses; adjust to maintain urinary cystine concentration below its solubility limit (generally less than 250 mg\/L)"},"1":{"id":"615025-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and efficacy have not been established in children less than 9 y<\/li><li><b>Cystinuria:<\/b> (9 y and older) 15 mg\/kg\/day in 3 divided doses, followed by adjustment to maintain urinary cystine below its solubility limit (generally less than 250 mg\/L)<\/li><\/ul>"},"3":{"id":"615025-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Cystinuria<br\/>"}}},"3":{"id":"615025-s-3","title":"Contraindications\/Warnings","sub":[{"id":"615025-s-3-9","title":"Contraindications","mono":"<ul><li>history of myelosuppression while on tiopronin<\/li><li>pregnancy and lactation<\/li><\/ul>"},{"id":"615025-s-3-10","title":"Precautions","mono":"adverse reactions more likely among patients who have shown toxicity to d-penicillamine<br\/>"},{"id":"615025-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"615025-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"615025-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Disorder of skin, Including pharyngitis, oral ulcers (17%)<\/li><li><b>Gastrointestinal:<\/b>Gastrointestinal symptom (17%), Taste sense altered (4%)<\/li><li><b>Immunologic:<\/b>Hypersensitivity reaction (4%)<\/li><li><b>Other:<\/b>Sense of smell altered (4%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Aplastic anemia, Leukopenia, Thrombocytopenia<\/li><li><b>Immunologic:<\/b>Drug-induced lupus erythematosus, Fever, arthralgia, lymphadenopathy<\/li><li><b>Renal:<\/b>Kidney disease (5%)<\/li><li><b>Other:<\/b>Drug fever<\/li><\/ul>"},"6":{"id":"615025-s-6","title":"Drug Name Info","sub":{"0":{"id":"615025-s-6-17","title":"US Trade Names","mono":"Thiola<br\/>"},"2":{"id":"615025-s-6-19","title":"Class","mono":"Renal-Urologic Agent<br\/>"},"3":{"id":"615025-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"615025-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"615025-s-7","title":"Mechanism Of Action","mono":"Systemic: Tiopronin is an active reducing agent that undergoes thiol-disulfide exchange with cystine (cysteine-cysteine disulfide) to form tiopronin-cystine disulfide, which is more water-soluble than cystine and is readily excreted. As a result, urinary cystine calculi are prevented.  <br\/>"},"8":{"id":"615025-s-8","title":"Pharmacokinetics","sub":{"3":{"id":"615025-s-8-26","title":"Excretion","mono":"Systemic: Renal<br\/>"}}},"9":{"id":"615025-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>administer 1 hour before or 2 hours after meals<\/li><li>administer at least 3 L of fluids per day including 2 glasses with each meal and at bedtime<\/li><\/ul>"},"10":{"id":"615025-s-10","title":"Monitoring","mono":"<ul><li>symptomatic improvement, reduction in stone formation<\/li><li>urinary cystine levels; at 1 mo, then every 3 mo<\/li><li>24-h urinary protein, urinalysis, CBC, serum electrolytes, hepatic function; 3-6 mo intervals<\/li><li>abdominal ultrasound of kidney, ureters, and bladder; yearly<\/li><\/ul>"},"11":{"id":"615025-s-11","title":"How Supplied","mono":"<b>Thiola<\/b><br\/>Oral Tablet: 100 MG<br\/>"},"13":{"id":"615025-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause oral ulcers or gastrointestinal symptoms including nausea, vomiting, diarrhea, anorexia, or abdominal pain.<\/li><li>Fever is more likely to develop during the first month of therapy. Tell patient to report fever.<\/li><li>Advise patient to report signs\/symptoms of kidney disease.<\/li><li>Patient should drink at least 3 L of liquids per day including 2 glasses with each meal and at bedtime, unless otherwise specified by healthcare professional.<\/li><li>Tell patient to take drug 1 h before or 2 h after meals.<\/li><\/ul>"}}}